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-Lactam antibiotics are extremely effective in disrupting the synthesis of the bacterial cell wall in both
gram-positive and gram-negative bacteria. However, they are ineffective againstMycobacterium tuberculosis, due
to the production of a -lactamase enzyme encoded on the chromosome of M. tuberculosis that degrades these
antibiotics. Indeed, recent studies have demonstrated that deletion of the blaC gene, the only gene encoding a
-lactamase in M. tuberculosis, or inhibition of the encoded enzyme resulted in significantly increased sensi-
tivity to -lactam antibiotics. In this paper we present a biochemical and structural characterization of M.
tuberculosis BlaC. Recombinant BlaC shows a broad range of specificity with almost equal penicillinase and
cepholothinase activity. While clavulanate is a mechanism-based inhibitor to class A -lactamase with high
potency (typically Ki < 0.1 M), it is a relatively poor inhibitor of the M. tuberculosis BlaC (Ki  2.4 M). The
crystal structure of the enzyme, determined at a resolution of 1.7 Å, shows that the overall fold of the M.
tuberculosis enzyme is similar to other class A -lactamases. There are, however, several distinct features of the
active site, such as the amino acid substitutions N132G, R164A, R244A, and R276E, that explain the broad
specificity of the enzyme, relatively low penicillinase activity, and resistance to clavulanate.
Penicillin G was the first -lactam antibiotic discovered, and
it was used extensively to treat bacterial infections from the
1940s to 1960s (5). Over the past 3 decades, many other
potent -lactam antibiotics, such as cephems, monobactams,
and carbapenems, have been developed and are currently be-
ing utilized to treat a wide range of bacterial infections. In fact,
the high efficacy, high specificity, and low rate of adverse re-
actions make -lactam antibiotics the most prescribed antimi-
crobial agents worldwide (12). All -lactam antibiotics show
structural mimicry to the natural substrates of the bacterial
DD-transpeptidases. DD-Transpeptidases, members of the pen-
icillin-binding protein family, catalyze the cross-linking of two
peptidoglycan strands, which is an essential step in bacterial
cell wall biosynthesis. Inhibition of DD-transpeptidases by
-lactam antibiotics leads to disruption of the synthesis of
the bacteria’s cell wall (13).
A significant increase in the number of -lactam-resistant
strains of pathogenic bacteria has been reported over the past
few years (35). Resistance to the -lactams primarily occurs
through the horizontal transfer of -lactamase genes contained
on plasmids (9). -Lactamases inactivate -lactam antibiotics
by efficiently hydrolyzing the amide group of the -lactam ring,
which is the prevalent mechanism of bacterial resistance to
-lactam antibiotics (13). -Lactamases are grouped into four
classes, A, B, C, and D, based on their amino acid sequence
homology and general enzyme catalytic properties (for a re-
view of -lactamases, see reference 13). Historically, class A
-lactamases were found to have much greater penicillinase
activity than cephalosporinase activity. However, several
new class A -lactamases that are active against new gen-
erations of cephalosporins and carbapenems have been dis-
covered. They are typically grouped as extended-spectrum
-lactamases (ESBLs) to differentiate them from the non-
ESBLs.
There have been few studies on the antitubercular effect of
-lactam antibiotics, probably due to the early discovery that
Mycobacterium tuberculosis possesses intrinsic resistance to
these antibiotics (25). The production of -lactamase has been
proposed to be the most significant reason for mycobacterial
resistance (7, 45, 55). Other factors that were believed to con-
tribute to the ineffectiveness of -lactam in M. tuberculosis
include cell envelope permeability and low penicillin-binding
protein binding affinity for -lactams (29, 53). Although M.
tuberculosis’s outer cell wall, formed by a waxy mycolic acid
layer, was thought to make a virtually impenetrable barrier,
-lactams have recently been shown to readily permeate the
M. tuberculosis cell wall and bind the penicillin-binding pro-
teins (7).
One approach that holds promise to counter M. tuberculo-
sis’s inherent resistance is to utilize -lactamase inhibitors in
combination with -lactam antibiotics to increase their efficacy
(7). For example, class A -lactamases are generally sensitive
to serine -lactamase inhibitors such as clavulanate and sul-
bactam (2, 17). These mechanism-based inhibitors covalently
cross-link two serines in the active site that are essential to the
hydrolysis of -lactams and permanently inactivate -lacta-
mase. The combinations of -lactam antibiotics and -lacta-
mase inhibitors have been used clinically to treat a wide range
of bacterial infections (35). These combinations have also been
shown to be somewhat effective against most strains of myco-
bacteria, including multidrug-resistant (MDR) strains in vitro
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(11, 48, 56). In fact, MICs of -lactams are less than 0.5 g/ml
for MDR strains of M. tuberculosis when used in combination
with both -lactamase inhibitors and the antitubercular drug
ethambutol (1). These results offer the possibility for treatment
of tuberculosis with highly potent inhibitors in combination
with -lactam antibiotics.
blaC (Rv2068c) is the only gene in the M. tuberculosis ge-
nome that shows any detectable homology to any of the known
-lactamase genes. Recently, the Pavelka laboratory showed
that the deletion of the blaC gene resulted in an increased
susceptibility of M. tuberculosis to -lactam antibiotics by 8- to
256-fold (14, 15), which confirmed the primary role of blaC in
M. tuberculosis resistance. In previous studies, partially purified
M. tuberculosis BlaC was classified as a class A -lactamase
type 2b based on its relatively high level of penicillinase activity
(6, 46). To fully characterize M. tuberculosis BlaC and facilitate
the design of new inhibitors, we have characterized the sub-
strate and inhibitor profile for BlaC and determined the struc-
ture of BlaC to high resolution.
MATERIALS AND METHODS
Cloning, expression, and purification. Escherichia coli expression plasmids of
the wild type and a truncated form (codons 41 to 307) of M. tuberculosis blaC
were cloned from genomic DNA (CSU N01-AI-75320). The amplified product
was inserted into pET28b (EMD Biosciences no. 69865-3) using the NdeI and
HindIII restriction sites. This plasmid was subsequently transformed into E. coli
BL21(DE3) (EMD Bioscience no. 69387-3) and cultured in Luria-Bertani–Miller
media containing 50 g/ml kanamycin at 37°C until the optical density at 600 nm
reached 0.8. Expression of the blaC gene was induced for 20 h at 16°C by addition
of 1 mM isopropyl -D-thiogalactopyranoside (IPTG). Cells were harvested by
centrifugation and resuspended in 25 mM Tris-HCl (pH 8.0), 500 mM NaCl, and
2 mM -mercaptoethanol and were lysed by French press. After treatment with
1 mM DNase I, the insoluble material was removed by centrifugation. By sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), full-length
BlaC goes into the insoluble pellet, while 90% of truncated BlaC (41–307)
remained soluble. Therefore, further purification was performed only on trun-
cated BlaC (41–307). The supernatant containing soluble protein was applied to
a Ni2-loaded HiTrap chelating column (AP Biotech) using a fast protein liquid
chromatography system and eluted through an imidazole gradient (0 to 0.5 M).
BlaC (41–307) was eluted at an imidazole concentration of 120 mM. Fractions
that contain BlaC (41–307) were pooled and dialyzed against 25 mM Tris-HCl
(pH 8.0), 40 mM NaCl, and 1 mM dithiothreitol. The samples were further
purified by gel filtration on a Superdex 200 column to separate the monomeric
protein from aggregated material using dialysis buffer. The protein was concen-
trated to approximately 10 mg/ml. BlaC (41–307) was obtained at 45 mg/liter of
E. coli culture and appeared homogeneous by SDS-PAGE and Coomassie blue
staining.
Kinetic assays. Enzyme kinetic evaluation was completed for the substrates
ampicillin (ε235  820 M1 cm1), cephalothin (ε262  7,660 M1 cm1),
cefoxitin (ε270  8,380 M1 cm1), ceftazidime (ε260  10,200 M1
cm1), and meropenem (ε299  2,500 M1 cm1) (24). All assays were
repeated in triplicate and carried out on a Cary 100 Bio spectrophotometer at
room temperature by monitoring the UV absorbance change of -lactams (24).
The M. tuberculosis BlaC activity assays were performed in 100 mM phosphate
buffer (pH 7.5) by adding 10 nM enzyme into substrate solution. Km and Vmax
were determined by analyzing a Hanes plot (57). Inhibition studies of clavulanate
were performed by adding enzyme into solutions containing the substrate am-
picillin and inhibitor clavulanate with increasing concentrations (0.1 to 600 M).
During the measurement time, no time-dependent loss of enzyme activity could
be detected. Values for Ki were determined from the x intercepts of a Dixon plot,
assuming competitive inhibition.
Crystallization of BlaC (41–307). Crystallization of the truncated enzyme,
missing the first 40 amino acids, was accomplished by the hanging-drop vapor
diffusion method (33). Initial crystallization conditions were discovered by sparse
matrix screen using crystal screens from Hampton Research. Hanging drops
containing 2 l of protein solution at 10 mg/ml and 2 l of buffer (0.1 M
Tris-HCl, pH 8.0, 2.0 M NH4H2PO4) were equilibrated at 16°C in Linbro plates
against 1 ml of the same buffer. Protein crystals appeared in 4 days as thin
plate-shaped clusters and were improved to larger rod-like clusters by cocrystal-
lization with its substrate ampicillin. Macroseeding was then used to obtain
high-quality single crystals.
Data collection and processing. A nearly complete diffraction data set to 1.7-Å
resolution was collected from a single crystal at 121°K using a cryoprotection
solution consisting of reservoir solution (0.1 M Tris-HCl, pH 8.0, 2.0 M
NH4H2PO4) with the addition of 20% glycerol. Beam line 14BMC at the Ad-
vanced Photon Source, Argonne National Laboratory, was used to collect the
data set using 1-degree oscillation widths over a range of 180°. The data were
integrated and reduced using HKL2000 (42). The completeness of low-resolu-
tion data is slightly lower, due to the ice rings caused by the high rejection rate.
Crystals of BlaC belong to the orthorhombic space group P212121 with the
following cell dimensions: a  42.74 Å, b  71.28 Å, c  85.17 Å,   90°,  
90°, 	  90°, with one molecule in each asymmetric unit.
Structure determination and model refinement. Initial phases were obtained
by molecular replacement with the computer program MolRep, part of the CCP4
package (3), using the related structure of -lactamase from Streptomyces albus
G (Protein Data Bank [PDB] identification [ID] 1BSG) (10) as a search model.
The best solution gave a correlation coefficient of 34.2% and a Rfactor of 50.9%
using data between 25- and 3-Å resolution. The structure from the molecular
replacement solution was refined with REFMAC, again in the CCP4 suite (3).
The first step in the refinement was to use rigid-body optimization, and this
resulted in a slightly improved model (Rfactor, 49.9%; Rfree, 51.8%; 54.6 to 1.7 Å).
Electron density maps were produced and manual rebuilding was carried out
using XtalView (34). The model was further refined with cycles of model building
and REFMAC restrained refinement (3). During the final cycles of the refine-
ment, water molecules were added based on peaks above 3-
 in the Fo  Fc
electron density maps that were within hydrogen-bonding distances from the
appropriate protein atom. The resulting structure had good geometry (88% of
the nonglycine residues were in the most favorable conformation, and none were
in a disallowed conformation) and an Rfactor of 17.9% and Rfree of 21.4%.
PROCHECK (3) revealed no disallowed  and , and the overall structure G
factor, a measure of a given stereochemical property, was consistently better than
expected for this resolution.
Structure analysis. DALI (22) was used to search the PDB for proteins having
folds similar to M. tuberculosis BlaC, in the order of structural similarity.
SwissPDB viewer was used to make structural alignments (19). The model was
evaluated and analyzed using computer graphic program SPOCK (8).
PDB identification. The atomic coordinates of BlaC have been deposited in
the PDB with the entry code 2GDN.
RESULTS AND DISCUSSION
Sequence analysis of BlaC. M. tuberculosis BlaC is a 307-
amino-acid protein that is predicted to have a signal peptide
for translocation into the periplasm and a lipid attachment site
(residues 14 to 24) using the computer program ScanProsite
(18). This analysis suggests that the mature BlaC is linked via
the covalently attached lipid to the outer leaflet of the inner
membrane after translocation to the periplasmic space. -Lac-
tamase lipoproteins have been reported for several gram-pos-
itive bacteria (39, 50). However, the enzyme was also predicted
using the SignalP program (4) to have a signal peptidase II
cleavage site at residue 28, which would eliminate the lipid
attachment site in the mature protein. It is therefore not clear
if BlaC exists free or as a membrane-bound protein in the
periplasm.
M. tuberculosis BlaC shares approximately 40% amino acid
sequence identity with other known class A -lactamases (Fig. 1).
Interestingly, it has the highest sequence identity to the class A
-lactamase of Streptomyces clavuligerus (54%), the bacterium
that produces the antibiotic cephamycin and the -lactamase in-
hibitor clavulanate.
Three highly conserved regions of the active site, designated
motifs I, II, and III, have been identified by multiple sequence
alignment of class A -lactamases from different bacteria. Mo-
tif I has a consensus sequence of Arg61-(Xaa)2-Glu-Xaa-Phe-
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(Xaa)3-Ser-Xaa-Xaa-Lys
73 (the residues of M. tuberculosis
BlaC were numbered according to a consensus ABL number-
ing scheme [2]), which extends from the end of the -strand B2
through a segment of the -helix H2. Motif II corresponds to
the sequence Ser130-Asp-Asn132 and is located between -he-
lices H6 and H7. Motif III, located on -strand B3, has the
consensus sequence Asp233-Lys-Thr-Gly236. Additionally, all
class A -lactamases have an  loop that in BlaC contains
residues Val159 to Thr180. While these regions are highly con-
served, BlaC from M. tuberculosis has several notable amino
acid substitutions. The substitution of a Gly for Asn at residue
132 occurs only in class A -lactamase from M. tuberculosis and
its closest homolog, S. clavuligerus -lactamase. The substitu-
tions R244A and R169A in M. tuberculosis -lactamase are
also rare in class A -lactamases. Another important difference
identified from amino acid sequence alignment is the four-
residue insertion Gly145A to Ala150 and the two-residue inser-
tion Gly271 and Tyr272 in the M. tuberculosis BlaC sequence.
Kinetic study. Initial attempts to express the full-length pro-
tein were unsuccessful. However, by truncating the codons for
the first 40 amino acids in our expression construct, we could
produce large quantities of active enzyme. This truncation was
not predicted to interfere with the enzyme’s catalytic function
based on what was known about homologous enzymes. The
molecular weight of the truncated protein was confirmed by
matrix-assisted laser desorption ionization (actual mass, 30,629
Da; calculated mass, 30,666 Da).
Kinetic measurements of the hydrolysis of the substrates
ampicillin, cephalothin, cefoxitin, ceftazidime, and mero-
penem, as well as the inhibition of the enzyme activity with
clavulanate, were carried out in order to compare the enzyme
activity to other class A -lactamases (Table 1). Overall, the
results show that M. tuberculosis BlaC has a broad-spectrum
substrate profile compared to other class A -lactamases.
While the penicillinase activity of BlaC (kcat/Km  293 mM
1
s1) is about 10-fold lower than most class A -lactamases, the
enzyme showed relatively good activity against cephalothin
(kcat/Km  103 mM
1 s1) in contrast to previous studies
where M. tuberculosis was shown to possess only minor cephalo-
thin activity (59). Indeed, we found that the cephalosporinase
activity of M. tuberculosis BlaC is comparable to its penicillinase
activity. Furthermore, BlaC shows modest activity (kcat/Km  10
mM1 s1) against cefoxitin, ceftazidime, and meropenem. Inhi-
bition studies indicated that clavulanate, a very potent inhibitor of
most of class A -lactamases (Ki  0.1 M), is a relatively poor
inhibitor of M. tuberculosis BlaC (Ki  2.4 M). The substrate
profile of BlaC is quite similar to that of Mycobacterium fortuitum
-lactamase, which also has relatively high cephalosporinase ac-
tivity (45).
Overall structure. The crystal structure of BlaC was solved
using molecular replacement and refined to 1.7-Å resolution.
The final Rfactor and Rfree values for all reflections were 0.18
and 0.21, respectively (Table 2). BlaC crystals are orthorhom-
bic, belonging to space group P212121, with one molecule in the
asymmetric unit. The refined structure of BlaC includes 265 of
the 267 residues in the truncated form of BlaC (41–307) and
248 ordered water molecules. The structure of the N-terminal
six-histidine tag along with the first two residues, Gly-Ala, was
not defined due to disorder of this region in the electron
density map. Like other class A -lactamases, the BlaC mono-
mer contains an  domain and an / domain. The  domain
consists of six long  helices (H2, H5, H6, H7, H9, and H10)
and three short  helices (H3, H4, and H8). The / domain
includes five antiparallel -strands (B1 to B5), the N- and
C-terminal  helices (H1 and H12), and one short  helix, H11
(Fig. 2). The overall structure of BlaC is very similar to other
class A -lactamase structures. The root mean square differ-
ences (RMSD) of the C atoms of several class A -lactamases
range between 0.95 to 3.66 Å and are listed in Table 3. The C
FIG. 1. Sequence alignment of  lactamases. Sequence alignment
of  lactamases from M. tuberculosis (BLAC), B. licheniformis (BS3), S.
albus (ALBS), E. coli (Toho-1 and TEM-1), E. cloacae (NMC-A), P.
vulgaris (K1), M. fortuitum (MYC), K. pneumoniae (SHV-1). Green,
completely conserved residues; yellow, identical residues; cyan, similar
residues. The important residues mentioned in the context are labeled.
The residues labeled by asterisks are the equivalents of those indicated
significant to the activity.
TABLE 1. Kinetic parameters of M. tuberculosis class A
-lactamase with different antibiotics as substrates
Class Antibiotic kcat(s1)
Km
(M)
kcat/Km
(mM1 s1) Ki (M)
Penicillin Ampicillin 18.5  0.9 63  7 293
Cephalosporin Cephalothin 12.1  1.1 117  14 103
Cefoxitin 1.1  0.3 195  15 5.6
Ceftazidime 0.2  0.1 593  29 0.4
Carbapenem
inhibitor
Meropenem 0.9  0.3 279  23 3.2
Clavulanate 2.4  1.1
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alignments of BlaC with other class A -lactamases of known
structure indicate that M. tuberculosis BlaC is more similar to
K1 (RMSD  0.95 Å) and NMC-A (RMSD  1 Å) (enzymes
from Proteus vulgaris and Enterobacter cloacae, respectively)
compared to SHV-1 and TEM-1 (RMSD  2.5 Å) (enzymes
from Klebsiella pneumoniae and E. coli, respectively). ALBS
(PDB ID 1BSG) was used as a search model because it dis-
played significant sequence homology to BlaC. Surprisingly, it
showed a fairly large RMSD value (3.66 Å) compared to BlaC.
Indeed, several other class A -lactamases with lower se-
quence homology are structurally more similar to BlaC.
Enzyme active-site structure. In all class A -lactamases, the
hydrolysis of the -lactam substrates is accomplished by a
nucleophilic attack initiated by active-site serine residue Ser70.
It has been proposed that Glu166, a general base in the active
site, is the serine70-activating residue based on the ultra-high-
resolution crystal structure (0.91 Å for SHV-2 and 0.85 Å for
TEM-1) studies (37, 41). However, others believe that Lys73 is
involved in the activation (49). Although the mechanism of
Ser70 activation is contentious (36), the deacylation mechanism
has been established. Glu166 has been demonstrated to be
critical for the deacylation of the acyl-enzyme intermediate
based on site-directed mutagenesis studies (23). The enzyme
active site is located at the interface between the  and the /
domains (Fig. 2). Ser70 and Lys73, located on -helix H2 in the
center of the active site (Fig. 3), are completely conserved in all
class A -lactamases and are surrounded by other key residues
on -strand B3 (Lys234, Thr235, and Thr237) and the loop re-
gion between H5 and H6 (Ser130 and Gly132), as well as the 
loop (Glu166). These eight residues are all involved in direct
hydrogen bonding interactions with -lactam substrates. Two
bound water molecules, WAT36 and WAT65, are also highly
conserved in the structures of all class A -lactamases deter-
mined to date. WAT65 is part of a hydrogen bond network with
the side chain oxygen of Ser70, as well as the side chain oxygen
of Glu166, both at a distance of 2.5 Å. This hydrolytic water
functions to deacylate Ser70 from the product after hydrolysis
of -lactam substrates (21, 31, 40). WAT36 is in the oxyanion
hole, forming hydrogen bonds with the backbone nitrogen of
Ser70 and the backbone nitrogen of Thr237 at distances of 2.6 Å
and 2.7 Å, respectively. Although ampicillin improved the dif-
fraction quality of the crystals, neither the substrate nor any
products could be identified in the active site.
Although the overall structure of M. tuberculosis BlaC is
similar to other class A -lactamases, some differences are
clear, the most obvious being the size of the active site (Fig. 4).
The active site of M. tuberculosis BlaC is significantly larger
than the other class A -lactamases with known structures.
Three factors that contribute to the increased size of the active
FIG. 2. A. BlaC structure and its secondary structures. The helices
are represented as H1 to H12 and the strands as B1 to B5. B. Stereo-
scopic view of C of BlaC labeled every 20 residues.
TABLE 2. Data collection, processing, and refinement statistics
Parameter Valueb for BlaC
Data collection
Maximum resolution (Å) .............................................. 1.72
Space group .................................................................... P212121
a (Å) ................................................................................ 42.7
b (Å) ................................................................................ 71.3
c (Å)................................................................................. 85.2
Unique reflections..........................................................25,908 (2,808)
Rsym
a (%)......................................................................... 11.4 (30.6)
Completeness (%).......................................................... 91.1 (100)
Redundancy .................................................................... 6.8 (6.9)
I/
 ..................................................................................... 23.2 (6.8)
Refinement statistics
Resolution range (Å)..................................................... 54.64–1.72
Number of reflections....................................................24,570
Number of atoms/subunit
Protein ......................................................................... 2,230
Solvent ......................................................................... 248
Rcryst (%) ......................................................................... 17.9
Rfree (%) .......................................................................... 21.4
Avg B factors (Å2)
Protein ......................................................................... 20.7
Solvent ......................................................................... 32.8
RMSD from ideal values
Bonds (Å).................................................................... 0.011
Angles (°) .................................................................... 1.44
a Rsym  hkli Iihkl  Ihkl/ hkliIihkl, where Ii is the intensity of
observation and I is the mean intensity of reflection.
b The numbers given in parentheses denote the respective values of the
highest-resolution shell.
TABLE 3. Structure comparison of class A -lactamases
from different species
Enzyme Source PDB ID Sequenceidentity (%)
RMSD
(Å)
BlaC M. tuberculosis
BS3 B. licheniformis 1I2S 47.3 1.57
ALBS S. albus 1BSG 45.0 3.66
Toho-1 E. coli 1IYS 46.5 1.87
SME-1 S. marcescens 1DY6 42.5 0.97
NMC-A E. cloacae 1BUE 41.1 1.00
K1 P. vulgaris 1HZO 42.9 0.95
MYC M. fortuitum 1MFO 40.7 1.54
SHV-1 K. pneumoniae 1SHV 40.0 2.74
TEM-1 E. coli 1BT5 38.0 2.85
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site are (i) amino acid substitution of several key residues, (ii)
rearrangement of conserved side chains, and (iii) a four-resi-
due insertion in the active-site region. The -lactam-binding
motif Ser-Asp-Asn is highly conserved among the class A
-lactamases. In M. tuberculosis BlaC, glycine occupies the
position of asparagine. In the class A -lactamases with struc-
tures determined thus far, the side chain of this asparagine
points toward the center of the active site, forming a hydrogen
bond with the side chain nitrogen of Lys73. The carbamide
group of the asparagine is in close contact with the ester car-
bonyl groups of penicillin and cephems in the complex struc-
tures published (47, 49). The 6-1R-hydroxyl group of imi-
FIG. 3. Stereo view of the substrate-binding site of M. tuberculosis BlaC.
FIG. 4. Stereo view of active sites in class A -lactamases. A. Superimposition of active sites of BlaC (green) and NMC-A (red). B.
Superimposition of active sites of BlaC (green) and Toho-1 (red).
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penem was also observed to hydrogen bond with the side chain
oxygen of Asn132 in the structure of E. coli TEM-1 (PDB ID:
1BT5) (32) and E. cloacae NMC-A (PDB ID: 1BUE) (51). It
was proposed that the extra space at this location, created by
about a 1-Å shift of Asn132 (equivalent to Gly132 in M. tuber-
culosis BlaC), and that its side chain pointing away from cat-
alytic center would accommodate the substituents at the R6
position of carbapenem and therefore increase carbapenemase
activity (38, 51). In fact, this is true for all the carbapenemases
of known structures. Having a glycine instead of asparagine in
this position makes the BlaC substrate-binding pocket wider
and likely more flexible. Therefore, this substitution in BlaC
offers an alternative approach to enlarge the active site and
could allow M. tuberculosis BlaC to specifically bind carbapen-
ems or cephems with large  substituents. Furthermore, on the
same side of the substrate-binding site as Gly132, the side chain
of Ser104 is unusual in that it is extended away from the sub-
strate-binding site. In other class A -lactamases, this position
is typically an asparagine or an aspartate and the side chain
points into the active site. Like the Asn132-to-Gly132 substitu-
tion, the conformation of the Ser104 side chain creates more
space in the active site and reduces the potential hydrogen
bonding interactions with the substrate. On -strand B3 of
BlaC, Thr237 is unusual for class A -lactamases. This location
is most often occupied by an alanine, as found in non-ESBLs,
or a serine in the ESBLs. The hydroxyl group of Thr237 points
to the same direction as the comparable serine in the ESBLs.
Ser237 (equivalent to Thr237 in M. tuberculosis BlaC) is believed
to play a critical role in the extended-spectrum activity of K1
(P. vulgaris) -lactamase. Superimposition of BlaC structure
with substrate-bound complex forms of Bs3 from Bacillus
licheniformis (PDB ID: 1I2W) and a mutant of the RTEM-1
from E. coli (PDB ID: 1FQG) (16, 49) indicates that Thr237
potentially forms three hydrogen bonding interactions with the
substrate: backbone oxygen to carbamide nitrogen of the 
substituent of -lactam (3.5 Å), backbone nitrogen to ester
carbonyl oxygen of -lactam (2.8 Å), and side chain oxygen
to carboxyl oxygen of the  substituent of -lactam (3 Å).
The side chain of Arg220 extends into the top part of the active
site, as illustrated in Fig. 5, and forms hydrogen bonds with the
side chain oxygen of Thr237, the backbone oxygen of Gly236,
and the ester carboxyl oxygen of bound -lactam. A similar
hydrogen bond is seen only in the carbapenemase NCM-A (E.
cloacae). The position of Arg220 is usually occupied by a serine
in ESBL type enzymes. The hydrogen bonding between Thr237
and Arg220 of M. tuberculosis BlaC pulls the side chain of
Thr237 about 2.5 Å away from the active site. This conforma-
tion helps to contain the relatively large substituents, such as
the 6-1R-hydroxyl group of carbapenems, which could be
critical for their binding. On the other side of the  sheets,
Arg243 is unusual for class A -lactamases. This position is
typically occupied by a threonine. The two nitrogens of the
guanidinyl group of Arg243 form hydrogen bonds with the
backbone CO group of Asp172 and Asn170 at distances of 2.8 Å
and 3.1 Å, respectively, and serve to link B4 with the  loop.
Another observed difference of potential importance is that
Arg171 in M. tuberculosis BlaC is usually either a threonine or
a serine in other class A -lactamases. The long side chain of
Arg171 extends toward the side of the entrance to the active
site. On the opposite site of the  loop, the region Ile102 to
Ile105 of BlaC is quite different from other class A -lactama-
ses. While all other class A -lactamases have either tyrosine
or histidine with their aromatic side chains covering the en-
trance, Ile105 at the same position makes BlaC’s active site 3
Å wider than other class A -lactamases. A four-residue in-
sertion, consisting of Gly145A to Thr145D, at the beginning of 
helix H7 makes H7 6 Å longer than that of other class A
-lactamases.
Structural basis for broad substrate profile. M. tuberculosis
BlaC has a broad-spectrum substrate profile. The penicillinase
FIG. 5. Comparison of hydrogen bond pattern involving residues
244 and 220 in M. tuberculosis BlaC (A) and class A -lactamase of
Bacillus licheniformis 749/C (B).
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activity of BlaC is about 10-fold lower than most of class A
-lactamases. However, the enzyme showed moderate activity
against cephalothin and some activity against cefoxitin, ceftaz-
idime, and meropenem. The broad substrate profile is due to
the enzyme’s large and flexible substrate-binding site, which
allows it to accommodate different types of substrates. While a
large active site can provide broader substrate specificity, it can
also lead to weak enzyme-ligand interactions. This could ex-
plain the generally low activity of M. tuberculosis BlaC in hy-
drolyzing substrates and inhibitors. The substrate profile of
M. tuberculosis BlaC is quite similar to the -lactamase of S.
clavuligerus; however, the M. tuberculosis enzyme has better
activity against all -lactams we have tested. The structure
suggests that the low penicillinase activity is in part due to the
Asn-to-Gly substitution at position 132. As a conserved residue
in other class A -lactamases, the nitrogen atom of the Asn132
side chain forms a hydrogen bond with the carbonyl oxygen of
the  substituent of -lactam substrates. Glycine at this posi-
tion would result in a loss of hydrogen bonding to the sub-
strate, as shown by the superimposition of Toho-1–benzylpen-
icillin (47) and M. tuberculosis BlaC structures (Fig. 6A and B).
The hydrogen bond is apparently important for stabilizing the
FIG. 6. A. Active site of Toho-1 in complex with benzylpenicillin. B. Active site of M. tuberculosis BlaC with a docked ligand benzylpenicillin,
using SwissPDB. C. Active site of E166A mutant SHV-1 in complex with the trans-enamine intermediate of tazobactam. D. Active site of M.
tuberculosis BlaC with a docked intermediate of tazobactam, using SwissPDB.
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substrate in the active site. Therefore, the loss of hydrogen
bonding interactions could explain the low activity of M. tuber-
culosis BlaC, especially to penicillin type substrates. The crit-
ical role of Asn132 in the activity of class A -lactamase has
been proven by the study of an N132A mutant of S. albus G
-lactamase (28), which showed a 100- to 200-fold decrease of
penicillinase and cephalosporinase activities. Unlike the
N132A mutant of S. albus G -lactamase, M. tuberculosis BlaC
has relatively good activity against cephalothin. The notable
R164A substitution in the neck of the  loop is likely the
reason why BlaC maintains good cephalothin activity. In other
class A -lactamases with known structures, this position is
always occupied by Arg164. Normally, Arg164 hydrogen bonds
to another highly conserved residue, Asp179, to form a salt
bridge in the neck of the  loop, which holds the  loop closed
and rigid (Fig. 7B). Loss of this hydrogen bond could poten-
tially destabilize the  loop (Fig. 7A), which has been shown to
play an important role in the expansion of activity against
cephalosporins, based on a mutagenesis study (54). Indeed,
compared to many other class A -lactamases, part of the 
loop region, Asn170 to Pro173, of BlaC is curved away from
B4 by 2 Å.
Several other residue substitutions could contribute to the
boost of cephalosporinase activity. Superimposition to struc-
tures of ESBLs in complex with cephalosporins indicated that
the hydroxyl group of Thr237 (equivalent to Ala237 or Ser237 in
other class A -lactamases) of M. tuberculosis BlaC occupies
the same position as the side chain of Ser237 in the ESBLs and
that the hydroxyl group is within the hydrogen bonding dis-
tance (2.5 Å) for the carboxyl group of  substituents of ceph-
alosporins. This could help to stabilize the acyl intermediate of
cephalosporins and increase the activity. This is consistent with
the finding that the A237T mutation increased the relative
cephalosporinase activity in TEM -lactamase (non-ESBL)
(20). Since S. albus G -lactamase is a non-ESBL at the equiv-
alent position, it has alanine, not serine or threonine. The loss
of the hydrogen bonding interactions at both sites could be the
reason why the N132A mutant totally lost cephalosporinase
activity.
Class A -lactamase inhibitors. Clavulanate is a suicide
inhibitor specific for class A -lactamases. This potent (Ki 
0.1 M) inhibitor forms a covalent acyl enzyme complex with
class A -lactamase. After acylation, the intermediate can ei-
ther tautomerize to form a transient inhibitor to the enzyme
or acylate another active-site serine, Ser130, to form a cross-
linked, irreversibly inactivated enzyme (58). Our inhibition
studies show that clavulanate is a relatively poor inhibitor of M.
tuberculosis BlaC (Ki  2.4 M) with a 24-fold-higher Ki com-
pared to TEM-1. Class A -lactamases with amino acid sub-
stitutions at Arg244, Asn276, Arg275, Met69, Met182, and Trp165
have been reported to be resistant to clavulanate and other
mechanism-based inhibitors (52). Among these residues, the
substitutions R244A, N278E, M69C, and M182T are all found
in BlaC. It is interesting that clavulanate is produced by S.
clavuligerus, whose -lactamase is the closest homolog of M.
tuberculosis BlaC. Not surprisingly, S. clavuligerus -lactamase
is resistant to clavulanate (Ki  12 M) (44). The superimpo-
sition of an E166A variant of SHV-1 with tazobactam bound
(43) and M. tuberculosis BlaC structures reveals that the
N132G substitution would also cause the loss of a hydrogen
bond between the side chain of Asn132 and 3--carboxyl group
of the inhibitor (Fig. 6C and D). In the complex structure of
wild-type SHV-1 with tazobactam bound, Asn132 was also ob-
served hydrogen bonding with the sulfinic acid group of the
trans-enamine intermediate (30). Based on the structure and
activity relationship, it is quite clear that M. tuberculosis and S.
clavuligerus share very similar strategies in the resistance of
general class A -lactamase inhibitors, that is, to weaken the
binding of the enzyme to those inhibitors mainly through the
single amino acid substitution N132G, even though this will
also sacrifice enzyme activity to other -lactam substrates.
BlaC has Ala244 on  strand B4. This position is usually
occupied by arginine in non-ESBL enzymes and threonine in
ESBL enzymes. Interestingly, in M. tuberculosis BlaC, the side
chain of Arg220 is almost in the same position usually occupied
by the side chain of Arg244 in other class A -lactamases. This
Arg220-Ala244 residue pair exists only in M. tuberculosis BlaC,
carbapenemase NMC-A (E. cloacae), and SCLA (S. clavuligerus).
Mutation of Arg244 to Ser in the TEM-1 -lactamase has been
shown to produce resistance to inactivation by clavulanate in
the mutant enzyme and resistance to ampicillin plus clavu-
lanate in a strain of E. coli producing this enzyme (27). The
modeling studies indicated that the guanidinyl group of Arg244
and an ordered water molecule stabilize the carboxyl group of
clavulanate and its acylated intermediate through hydrogen
bonding (26). In the R244S mutant, these hydrogen bonds
FIG. 7. Comparison of the  loops comprising residues 160 to 179
of M. tuberculosis BlaC (A) and SHV-1 (B).
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would be lost, which could potentially cause resistance to clav-
ulanate. It is tempting to speculate that the R244A substitution
in BlaC would have a similar mechanism of resistance to clav-
ulanate. However, the position of the Arg244 side chain in
TEM-1 is occupied by the guanidinyl group of Arg220 in BlaC,
which does not exist in TEM-1 (Fig. 5); this complicates the
situation. Even though the water molecule in the TEM-1 struc-
ture that is believed to be important to clavulanate inhibition is
not observed in the BlaC structure, and the guanidinyl group of
Arg220 in BlaC does not have the same orientation as that of
Arg244 in TEM-1, it is possible that the presence of the gua-
nidinyl group of Arg220 could to some degree restore the sen-
sitivity of BlaC to clavulanate. Indeed, the resistance of BlaC to
clavulanate (Ki 2.4 M) is about 10-fold less than the R244S
mutant of TEM-1 (Ki  33 M) (26). However, the clavu-
lanate inhibition is biphasic, and Ki reflects only the first phase.
Arg244 in TEM-1 has been shown to be important to both the
binding of clavulanate and the chemistry of inactivation (26).
Arg220 in BlaC may be able to help the binding of clavulanate
by a hydrogen bonding interaction in the first phase but is not
likely to facilitate the chemistry of inactivation in the second
phase.
Although clavulanate is not an ideal inhibitor to M. tuber-
culosis BlaC, it has been demonstrated that the combinations
of -lactam antibiotics and mechanism-based inhibitors such as
clavulanate are effective in the treatment of M. tuberculosis,
even MDR strains. This makes M. tuberculosis BlaC a prom-
ising target for the design of new inhibitors that are specific
for and potent against M. tuberculosis BlaC. Based on the
structure of M. tuberculosis BlaC, it is now possible to either
modify current inhibitors to increase inhibitory potency or
design novel inhibitors that are specific for the enzyme. In
combination with the highly potent M. tuberculosis BlaC
inhibitors, -lactam antibiotics could become a new regimen
to treat tuberculosis.
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